Ask My Investor AI
Public company · NYSEPublished company research
ZBH

Identity verified against Zimmer Biomet Holdings, Inc.'s SEC Form 10-Q for the quarter ended March 31, 2026, CIK 0001136869.

Zimmer Biomet Holdings, Inc.

Zimmer Biomet reports product categories centered on knees, hips, sports medicine and extremities, and technology and data. Q1 2026 net sales were $2.0867 billion; knees contributed $828.6 million and hips $524.1 million. These reconstruction products can support mobility, but the issuer does not report an aging-in-place revenue category, so demographic attribution remains analytical and NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
ZBH
Exchange
NYSE
HQ
United States
Currency
USD
SEC CIK
0001136869
Investment case

How this company captures the theme economics

Competitive position

The Q1 2026 filing supports scale across knees, hips and other musculoskeletal categories and reports growth associated with market growth, new products and transaction effects. It does not directly support a comparative market-share ranking.

Scarce assets

The reviewed filing supports a broad reconstruction portfolio and technology products including ROSA Robot. Surgeon adoption, installed-base effects and switching costs require further primary-source review.

Products, segments, and customers

Zimmer Biomet reviews sales across Knees, Hips, S.E.T. (sports medicine, upper extremities, foot and ankle, trauma, craniomaxillofacial and thoracic), and Technology & Data, Bone Cement and Surgical.

Theme capture

Knees and hips together generated $1.3527 billion of Q1 2026 net sales. The products have a plausible mobility connection, but the filing does not quantify sales by patient age or aging-in-place use.

Conditions

What must be true

  1. Knee, hip and enabling-technology demand must remain durable after acquisition, currency and quarter-end purchasing effects are separated.
  2. A human reviewer must confirm materiality to Aging in Place without presenting inferred demographic exposure as issuer-reported fact.

Identifiable catalysts

  • Quarterly knee, hip and technology-category growth from SEC filings
  • Primary-source evidence on ROSA adoption and procedure-volume durability
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Orthopaedic reconstruction and enabling technology, including hip and knee implants.

Aging-in-place economy

Q1 2026 net sales were $2.0867 billion, including $828.6 million from knees and $524.1 million from hips. The filing says knees and hips benefited from customer purchases, market growth and new-product introductions.

Evidence
The SEC Form 10-Q replaces the prior secondary summary and directly supports the reported figures. It does not quantify older-adult or aging-in-place revenue.
Materiality
disclosed — Knees and hips together represented $1.3527 billion of $2.0867 billion Q1 2026 net sales; demographic attribution is not disclosed.
Financial evidence

Official SEC filing evidence

Reference period: Q1 2026.

  • Net sales$2.0867 billion
    Q1 2026[2]
  • Net-sales growth9.3%
    Q1 2026[2]
  • Knees net sales$828.6 million
    Q1 2026[2]
  • Knees growth4.5%
    Q1 2026[2]
  • Hips net sales$524.1 million
    Q1 2026[2]
  • Hips growth5.7%
    Q1 2026[2]
  • Net earnings$238.1 million
    Q1 2026[2]
  • Operating margin17.9%
    Q1 2026[2]

Limitation: The filing establishes current product-category and financial performance. Acquisition contribution, currency, quarter-end purchasing and product timing affect the comparison; aging attribution and current valuation are not established.

Risks

Material risks and break conditions

Material risks

  • Q1 2026 growth included contributions from the Paragon 28 acquisition, foreign exchange and opportunistic end-of-quarter purchases.
  • Pricing pressure, procedure-volume variability, new-product execution and integration costs can affect reported growth and profitability.

Thesis-break conditions

  • Knee and hip growth fails to persist after acquisition, currency and timing effects are separated.
  • Primary research fails to establish a material, durable connection between reconstruction demand and the Aging in Place thesis.
Investability conclusion

Where the evidence lands

Current SEC evidence supports identity, reconstruction exposure and reported financial scale. Demographic attribution, durable competitive advantage, current valuation and human acceptance remain unresolved; the subject is NOT_READY.

Next diligence

  1. Separate organic performance from Paragon 28, currency and timing; quantify ROSA adoption and procedure-volume trends; complete licensed valuation and independent human review.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Zimmer Biomet Holdings, Inc. FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-20 · accessed 2026-07-22
  2. Zimmer Biomet Holdings, Inc. Q1 2026 Form 10-QSEC EDGAR · primary · published 2026-04-28 · accessed 2026-07-29